Joint Corp
NASDAQ:JYNT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.62
17.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Joint Corp
Earnings Call Analysis
Q4-2023 Analysis
Joint Corp
In the face of uncertainty and challenges within their market, the company has persevered to deliver noteworthy growth. They have managed to increase system-wide sales, revenue, adjusted EBITDA, and patient counts, both new and returning. Not only did the number of unique patients and patient visits rise year over year, but the membership model has also grown stronger, with monthly memberships now accounting for a substantial portion of the system-wide gross sales. A clear testament to their marketing strategies and patient engagement efforts paying off. This persistence and innovative approach allowed them to close the year with a solid increase in key operating metrics and financial outcomes, showcasing the company's capability in navigating a turbulent market environment.
The financial narrative of 2023 is one of success. System-wide sales amplified to $488 million, a 12% rise in comparison to 2022. The company saw its comp sales increase alongside revenue, which shot up by 16%. Adjusted EBITDA also experienced an uplift, enhancing the company's profitability. Furthermore, a significant upswing in unrestricted cash reserves compared to the previous year strengthens the company's financial position. This financial performance reveals a promising trajectory and a firm foundation for sustained growth.
The company continued to expand its footprint, opening a notable number of new clinics across franchise and greenfield models, although this was a slight decrease from the previous year. They maintained operational efficiency by keeping closures under 2% of their total portfolio, asserting the strength and persistence of their business model in a competitive landscape. The shift in clinic portfolio mix towards an increased franchise ratio highlights a strategic maneuver as part of their refranchising strategy, placing trust and operational control into the hands of local franchisees.
The refranchising strategy, a significant pivot in the company's business model, is underway with a well-structured process designed to maximize value. Abundant interest from potential buyers indicates a strong market for their corporate clinics. Proceeds from these sales promise to fuel reinvestment in brand marketing and other strategic initiatives, symbolizing a wise capital allocation strategy aimed at long-term growth and shareholder value enhancement.
New franchise license sales slowed, as expected, due to the refranchising announcement and economic factors including higher interest rates. Noteworthy is a majority of sales being to existing franchisees, emphasizing their belief in and commitment to the brand. Even with market challenges and a refocused direction, the company managed to sell a respectable number of new licenses last year.
In consideration of the complexities introduced by their strategic refranchising efforts, the company did not provide specific guidance on franchise sales or revenue declines for FY '24, acknowledging the uncertainty around the timing of clinic sales affecting GAAP revenue recognition. This reveals a prudent approach, choosing to focus on metrics with higher predictability and clarity for stakeholders.
The company is reinvigorating its marketing endeavors, harnessing new strategies and auditing media buys to maximize impact. A focus on leveraging influencers and optimizing cooperative marketing efforts highlight a shift towards a more collaborative and potent marketing strategy. Additionally, the company aims to improve patient retention, recognizing previous gaps in extending patient relationships and addressing them to enhance overall unit economics, which ultimately contributes to bottom-line growth.
Sales and marketing expenses saw a sequential decline from previous quarters but are expected to normalize in the coming year. Importantly, the bulk of marketing efforts occur at the local franchise level, reflecting a decentralized approach that positions franchisees at the forefront of their own growth. Meanwhile, General and Administrative (G&A) expenses, a significant focus for management, are expected to decrease as the refranchising strategy progresses, which aligns with the company's focused attempt at cost containment and maximizing financial efficiency across their operations.
You don't have any saved screeners yet
Good afternoon, everyone, and welcome to The Joint Corp. Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] Please also note, today's event is being recorded.
At this time, I'd like to turn the floor over to Kirsten Chapman with LHA Investor Relations, a division of Alliance Advisors. Please go ahead.
Thank you, Jamie. Good afternoon, everyone. This is Kirsten Chapman of LHA Investor Relations, a division of Alliance Advisors. Joining us on the call today are President and CEO, Peter Holt; and CFO, Jake Singleton. Please note, we are using a slide presentation that can be found at ir.thejoint.com/events. Today, after the market closed, The Joint issued its results for the quarter and year ended December 31, 2023. You can find that press release on the Investor Relations section of the company's website.
As provided on Slide 2, please be advised that today's discussion includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be considered forward-looking statements. Although the company believes that the expectations and assumptions reflected in these forward-looking statements are reasonable, it can make no assurances that such expectations or assumptions will prove to have been correct. Actual results may differ materially from those expressed or implied in forward-looking statements due to various risks and uncertainties. As a result, we caution you against placing undue reliance on the forward-looking statements.
For a discussion of the risks and uncertainties that could cause actual results to differ from those expressed or implied in the forward-looking statements, please review the risk factors detailed in the company's reports on Forms 10-K and 10-Q, as well as other reports the company files from time to time with the SEC. Finally, any forward-looking statements included in this call are made only as of the date of this call, and we do not undertake any obligation to revise our results or publicly release any updates to the forward-looking statements in light of any new information or future events.
Management uses EBITDA and adjusted EBITDA, which are non-GAAP financial measures. These are presented because they are important measures used by management to assess the financial performance. Management believes they provide a more transparent view of the company's underlying operating performance and operating trends than GAAP measures alone. A reconciliation of the net income to EBITDA and adjusted EBITDA is presented in the press release. The company defines EBITDA as net income or loss before net interest, tax expense, depreciation and amortization expenses.
The company defines adjusted EBITDA as EBITDA before acquisition-related expenses, which includes contract termination costs associated with reacquired regional developer rights, stock-based compensation expense, bargain purchase gain, net loss or gain on disposition of impairment, costs related to restatement filings, restructuring costs and other income related to employee retention credits.
Management also uses commonly discussed performance metrics. System-wide sales includes revenues at all clinics, whether operated by the company or by franchisees. While franchise sales are not recorded as revenues by the company, management believes this information is important in the understanding of the company's financial performance because these sales are based on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. System-wide comp sales includes the revenue from both company-owned or managed clinics and franchise clinics that in each case have been opened at least 13 full months and exclude any clinics that have been closed.
Turning to Slide 3, it is my pleasure to turn the call over to Peter Holt. Please go ahead, Peter.
Thank you, Kirsten, and I welcome everybody to the call. As we review 2023, I'd like to begin by acknowledging how proud I am of our whole team, our doctors, wellness coordinators, corporate employees, franchisees and regional developers for their steadfast commitment to supporting our patients. In a market of ongoing uncertainty among our patient demographic, we delivered growth in system-wide sales, revenue, adjusted EBITDA, the number of new patients, and the number of patients treated. Also, we improved our patient conversion and existing patient attrition rates. I'm even more impressed as they embraced our enhanced marketing strategies targeted to increasing new patient count and improving existing patient engagement. Our efforts are beginning to gain traction, and we're augmented by our year-end campaign.
The Joint is revolutionizing access to chiropractic care by providing a portable, concierge-style membership-based services in convenient retail settings. And this franchise concept remains strong. In fact, there's been significant interest in our refranchising strategy as we announced at the last -- at the end of last year. We put a thoughtful process in place to ensure that we are getting these clinics into the hands of our franchisees who can most effectively run them.
As we move into 2024, we've renewed our mission to improve quality of life through routine and affordable chiropractic care, and we've advanced our vision to be the champion of chiropractic. Jake and I will elaborate. But first, I'd like to review our 2023 operating metrics.
During the year, the doctors of chiropractic at The Joint performed 13.6 million adjustments, up from 12.2 million patient visits in 2022. We treated 1.75 million unique patients, up from 1.6 million in 2022. And of those treated, over 932,000 were new to patients -- new patients, up from approximately 845,000 in 2022. Of our new patients, 36% or approximately 336,000 people had never been to chiropractic before visiting The Joint. Our model is literally expanding the market of chiropractic users. Finally, during 2023, our monthly memberships contributed 85% of our system-wide gross sales, up from 84% in 2022.
Turning to Slide 4, I'll review our financial highlights for the full year 2023. System-wide sales grew to $488 million, increasing 12% compared to 2022. Comp sales for clinics that has been open more than 13 full months increased 4% compared to 2022. Revenue increased 16% compared to 2022. Adjusted EBITDA was $12.2 million for 2023, up 6% over last year. At December 31, 2023, our unrestricted cash was $18.2 million compared to $9.7 million at December 31, 2022.
Turning to Slide 5, I'll discuss our clinic metrics for 2023. We opened 114 clinics: 104 franchise and 10 greenfields. This compares to 2022 with 137 clinics opened, 110 franchise and 20 greenfields. We closed 13 franchise and 4 corporate units, which is less than 2% of our portfolio. This reflects the fact that some of the clinic market conditions changed. For example, a retail center may lose an anchor tenant or other demographic changes impact viability of the site. Having said that, we're working on a number of profitability initiatives to improve financial performance of our clinics. We added 3 previously franchised clinics to our corporate portfolio. At December 31, 2023, we had 935 clinics in operation, consisting of 800 franchise clinics and 130 company-owned or managed clinics. The clinic portfolio mix shifted slightly to 86% franchise and 14% company-owned and managed from 85% to 15% at the end of 2022. As we execute our refranchising strategy, the portfolio mix will shift more significantly.
Regarding our corporate portfolio, while we're no longer proactively pursuing a greenfield expansion strategy, we're actively supporting the 3 greenfield clinics that are in the process of being opened. We will uphold our various obligations related to their leases and build-outs.
Turning to Slide 6, regarding our franchise -- our refranchising strategy. As noted before, many of these clinics are quality assets of high value, and we will allow the necessary time to capture that best value. Our team has prepared the framework for the sale of the majority of our corporate clinics. We've organized units and clusters and generated comprehensive disclosure package for marketing efficiently. We gave initial preference to existing franchisees and have broadened the net to potential buyers outside the existing Joint community. The majority of our corporate clinics are at various stages of sales negotiations. We intend to sell these clinics to our franchisees who can most effectively run them.
Today, we've received significant interest with over 100 requests for information. Later this month, we'll be marketing at the multi-unit franchise conference in Las Vegas. Ultimately, our goal is to get these clinics in the hands of our best-performing franchisees, generate capital that can be used for many purposes, such as reinvesting in the brand marketing, reacquiring RD territories and/or repurchasing stock, among other options.
Turning to Slide 7, let's review our franchise license sales. As expected, when we announced our new refranchising strategy, we experienced a slowdown in new franchise license sales. While there will be some franchisees that want to start with a brand-new clinic and continue to purchase new licenses, we expect the speed of new franchise sales to be impacted while the refranchising is in full swing.
During Q4, we sold 5 franchise licenses, bringing the 2023 sales to 55 compared to 75 in 2022. The year-over-year change reflects the continued impact of the higher interest rates, inflation, strong employment rates, in addition to our newly announced refranchising strategy. Of licenses sold, 58% were sold to existing franchisees who reinvested in The Joint, reflecting their belief in our business. At year-end, we had 172 license -- franchise licenses in active development. Our marketing efforts, which I'll detail more in a moment, are built to support our nationwide brand-building efforts.
Our regional developer strategy remains consistent. We have demonstrated over the past several years that the natural progression of territory development can lead to the reacquisition of certain RD regions, and we'll continue to execute as criteria is met. We do not plan to add additional RD territories. And as such, over time, we'd expect RD share franchise royalty fees to decrease as we acquire those RD rights. We ended 2023 with an RD count of 17, and the aggregate 10-year minimum development schedule for the RD territories is 674.
Turning to Slide 8. Let's review our key performance indicators. We've taken great measures to increase our new patient conversion rates, grow new patient counts and lower patient attrition. In 2023 compared to 2022, we improved attrition by 20 basis points to 11%. Also, conversions rose 160 basis points to 52.1%, and we're continuing to work hard to increase our new patient counts. I'll review our marketing efforts related to that on Slide 9.
Back Friday and year-end wellness sales were both strong promotions for us in 2023, resulting in a new record-breaking totals in several areas. Total sales for the Back Friday packages increased 31% compared to 2022. The annual end of year wellness sale helped the patients start the new year with wellness in mind. This promotion enabled our patients to purchase 10 months of membership and received 2 months free. Total end-of-year promotional sales increased 21% compared to 2022. In 2024, it's shaping up to be an exciting year for marketing as our Joint -- at The Joint led by our new CMO, Lori Abou Habib. We focused on initiatives to drive new patients including increasing our media efficiency by adjusting our channel mix and increasing our working media spend to reach even more prospective patients. This adjusted media mix pairs with our patient strategy to ensure that we're delivering the message of affordable, convenient chiropractic care to those most likely consumers.
Additionally, we plan new promotions and offers aimed directly at adding new patients. To take advantage of our local differences, we're creating more robust local store marketing programs by providing proven tactics and more nuanced tools for our system. Finally, to ensure that we maximize convenience for our patients, we're testing an initiative to enable initial patient bookings, something that we're learning is important to a subset of our prospective patients. Additionally, we're putting a greater focus on existing and lapsed patient engagement. We will introduce new promotions aimed at reengaging former patients. Moreover, we'll apply our learnings about the patient life cycle to automated messages to retain patients during the critical phases of their journey. In partnership with our marketing co-ops, we're testing new programs and channels to increase our co-op synergies and overall brand awareness.
The marketing team has been working hard on expanding the brand's architecture. We continue to evolve our brand positioning and defining the brand essence to deepen our competitive advantage. During Q4, we had several workshops to define current consumer perceptions, our target consumers and unique benefits that we can offer as a brand. More recently, we had an opportunity to work with our franchisees to incorporate their feedback into the process. We're refining language and defining impact areas to leverage this new positioning. We expect these efforts to have a positive impact on our performance in 2024.
And with that, I'll turn the call over to Jake.
Thanks, Peter. Let's turn to Slide 10. I'll review our clinic comps for Q4 '23 compared to Q4 '22. System-wide sales for all clinics opened for any amount of time increased to $133.1 million, up 11%. System-wide comp sales for all clinics opened 13 months, increased 5%. System-wide comp sales for mature clinics opened 48 months or more, decreased 1%. Revenue was $30.6 million, up $2.9 million or 11%. Revenue from franchised operations increased 14%, contributing $12.7 million. Company-owned or managed clinic revenue increased 9%, contributing $17.9 million. The increases represent continued year-over-year growth in both the franchise base and the corporate portfolio. Cost of revenues was $2.9 million, up 16% over the same period last year, reflecting the associated higher regional developer royalties and commissions.
Selling and marketing expenses were $3.4 million, up 2% year-over-year, and down 22% compared to Q3 '23. This reflects our Q4 cost management efforts to offset selling and marketing spending earlier in the year.
Depreciation and amortization expenses decreased $379,000 or 18% compared to the prior year period, reflecting the corporate clinics that are being held for sale as part of the refranchising efforts.
General and administrative expenses were $21.3 million compared to $18.3 million, reflecting the cost to support the increased clinic count. These were partially offset by cost control initiatives such as hire increases, travel reductions and the elimination of noncore projects.
Loss on disposition or impairment was $1.5 million compared to $50,000 in Q4 '22. The increase is related to our refranchising efforts, which include those additional corporate clinics that were announced to be held for sale in November of 2023.
Operating loss was $147,000 compared to operating income of $1.5 million in Q4 2022, reflecting the aforementioned impairment charges.
During Q4, we recorded a noncash valuation allowance of $10.8 million against our deferred tax assets. A valuation allowance is a noncash accounting entry to record a reserve against existing deferred tax assets. As we mentioned earlier, there is uncertainty regarding the timing of our refranchising transactions. When you introduce uncertainty, the GAAP accounting guidance indicates you should review the potential realizability or our ability to benefit from those future tax assets. Until such time that those uncertainties are resolved, it's more prudent to record a valuation allowance at this time. It's important to note that we still maintain these tax assets, and they will be available to utilize in the future as we return to profitability. As a result, income tax expense was $10.9 million compared to $629,000 in Q4 2022.
Q4 2023 net loss was $11.0 million or $0.75 per share compared to Q4 2022 net income of $763,000 or $0.05 per diluted share. Adjusted EBITDA was $4 million for both Q4 2023 and 2022. Franchise clinic adjusted EBITDA was up 11% at $6.6 million. Company-owned or managed clinic adjusted EBITDA increased 15% to $1.8 million. Corporate expense as a component of adjusted EBITDA was $4.4 million, $814,000 higher than Q4 2022 related to increased head count to support the larger clinic count.
On to Slide 11 for the year ended December 31, 2023, compared to 2022. System-wide sales for all clinics opened for any amount of time increased 12%. System-wide comp sales for all clinics opened 13 months or more increased 4%. System-wide comp sales for mature clinics opened 48 months or more decreased 1%.
Revenue was $117.7 million, up $16.4 million or 16%. 2023 net loss, including the noncash valuation allowance was $9.8 million or $0.66 per basic share. This compares to 2022 net income of $627,000 or $0.04 per diluted share. Adjusted EBITDA was $12.2 million, up $691,000 or 6%.
On the review of our balance sheet and cash flow. At December 31, 2023, our unrestricted cash was $18.2 million compared to $9.7 million at December 31, 2022. This reflects $14.7 million in cash from operations, including the receipt of employee retention credits of $4.8 million, net of $6.2 million investment in clinic acquisitions, development of greenfield clinics and the improvement of existing clinics and corporate assets.
At December 31, 2023, we had $2 million drawn on our line of credit with JPMorgan Chase. Since year-end, based on our high closing cash balance and our projected proceeds from the refranchising strategy, we decided to reduce our interest expense and repaid the $2 million line of credit balance. We continue to have immediate access to $20 million of additional cash through this line of credit with JPMorgan Chase.
On to Slide 12, for a review of our guidance. As Peter discussed, we are well into our refranchising strategy. Because of the timing of the corporate clinic sales is uncertain and will impact the revenue and adjusted EBITDA in 2024, we have modified financial guidance to be system-wide gross sales and system-wide comp sales. We will continue to provide guidance on new franchise openings, excluding the impact of refranchised clinics.
System-wide sales are expected to be between $530 million and $545 million compared to $488 million in 2023. System-wide comp sales for all clinics opened 13 months or more are expected to increase in the mid-single digits compared to an increase of 4% in 2023. New franchise clinic openings, excluding the impact of refranchised clinics are expected to be between 60 and 75, compared to 104 in 2023. The difference reflects the impact of the refranchising efforts.
As we think about the financial impacts of the refranchising efforts, please note that our cost of sales is primarily related to regional developer fees, and we expect it to remain fairly static. We expect our sales and marketing expenses to decrease as we reduce the scale of our corporate portfolio. Currently, our corporate clinics spend about $3,000 per clinic per month in local advertising.
Regarding general and administrative expenses, we expect to see significant reductions in our clinic level, 4-wall operating expenses or outside the 4-wall expenses and in our unallocated corporate overhead. These expenses will be reduced proportionately as we reduce the scale of our corporate portfolio. As such, the timing of these G&A reductions will be gradual and incremental. Overall, while we reduced our top line revenue, we expect reductions in G&A to expand our operating margins and increase profitability in the long run.
Finally, it's important to note that while some of our underperforming clinic valuations may result in noncash impairment charges, the better the clinic performs -- however, the better clinic performs, it will create higher sales proceeds and the opportunity for a gain on sale.
And with that, Peter, I will turn the call back over to you.
Thank you, Jake. As I noted on the onset of this call, we've expanded our vision to be the champion of chiropractic care by providing consumers expanding access to chiropractic services that meets the demands and improve their health. Our strategic pillars are our brand, our people, and our performance.
To elevate our brand equity and drive awareness, we'll strive to increase our active patient count by improving the intake process by testing book -- booking new visit -- patient initial visit and by optimizing local clinic marketing. We plan to lengthen the time patients stay engaged with The Joint, and to reactivate lapsed patients by leveraging new content, automated messaging and additional promotions. Also, we intend to employ new media campaigns to increase our new patient leads. Our goal is to ensure we assemble and retain the strongest team. We are continually building our lead pipeline to our doctors of chiropractic to share with our whole franchise system by cultivating professional relationships and mentoring programs. We're evaluating and recommending enhanced incentives and benefits, including creating The Joint's first continuing education platform for our doctors. Additionally, we're employing programs that better align staff with our patient experience vision.
These initiatives are being implemented to improve our performance. We expect to drive total system sales by increasing new patient counts and optimizing sales per patient. Additionally, we're evaluating the line extensions and ancillary products. Ultimately, we expect to foster our strong franchise base, improve unit economics, increase productivity and expand margins at the clinic and company level.
Finally, The Joint is consistently recognized for our excellence. Most recently, Entrepreneur Magazine ranked The Joint #1 franchise in chiropractic services, #61 for veterans, and #83 of the top 500 franchise systems in the United States.
Before we begin questions, I'd like to invite you to meet us at the ROTH Annual Growth Conference later this month in Orange County. And with that, Jamie, I'm ready to take the Q&A.
[Operator Instructions] Our first question today comes from George Kelly from ROTH MKM.
Maybe I'll start with -- trying to just get a feel for the process, the refranchising process underway. And there was a comment, I think, in your prepared remarks, and it's in the slide deck as well, just about how you're sort of broadening the scope of potential buyers of those businesses. And I'm just curious, is it fair to interpret that as like the initial interest has maybe lacked your previous expectation? Or how should I interpret that comment in the presentation?
And then the second part of the question, same topic, is -- do you have a better sense of timing when this process should be complete? Are you comfortable? Should it be a year-end thing? Or could this be several years?
George, 2 great questions. To answer your first question is that it somehow by the idea of broadening the people that could potentially interested in our franchise clinics that we're selling a reflection of lower interest than expected of our franchise community, absolutely not. What we've also recognized is the most important thing for us to get these clinics, not just off our balance -- off our books, but to get them in the hands of franchisees who can most effectively run them. And we recognize that it makes sense, at the same time as working closely with the interest in our franchisees, in terms of acquiring some of these clusters that we've created, but they also be open to some other alternatives. And so that was really the purpose there. It's just to broaden the scope of what we're looking for to make sure that we're getting the best franchisees in the system.
Your second question was getting a better sense of the timing of it. And I would say that, we're still a little early in the process. As I said, we've got all of our systems in place, we've done the clustering, we're in our conversations with our franchisees. That -- I don't have the exact timeline to give you, but I would expect, let's say, we should see a significant amount of this clinic sold by this year, but I would expect it to also go into 2025.
And then just 1 other question for you. Wondering if you could -- I appreciate the guidance you gave, that's helpful, just those are key metrics for the year. But curious if you could just maybe give a little more on what you've seen so far in this year, just in the couple of months on same-store sales growth. And has it improved from what you just reported in Q4? Or is it kind of consistent? Just any observations there would be helpful. And that's all I had.
If you look at -- typically, George, we do not guide outside of quarters. But as we look in the first 2 months of 2024, I would say we're -- and I kind of referenced it in the call, is that we're kind of seeing a turn in the corner in our new patient counts. And so I think that we're seeing some improvement as we look forward for this year and beyond.
And our next question comes from Ryan Meyers from Lake Street Capital.
Just a little bit of a follow-up to the last question. But as I look through the slide deck, it looks like the more mature clinics, one is greater -- opening greater than 48 months, saw a slight decline in same-store sales. Just wondering if you could maybe unpack that a little bit or if there's any more commentary you can provide there?
Yes. Consistent results to last quarter, Ryan. We have seen that trend for the last couple of quarters, and I think that's why you see the continued emphasis on our marketing efforts, not only trying to show the rebound in those new patient prospects, but also increasing our focus on our lapsed or try to increase engagement of our existing patient base. As clinics mature and your markets become more dense, you have a greater amount of prospects in order to kind of refill the bucket, if you will, from an attrition standpoint. So it has to remain a critical focus of ours. And I think you heard that in terms of our renewed interest and focus in some of those marketing initiatives.
Got it. And then just kind of as a brief follow-up to that question. Obviously, the marketing strategy remains kind of a priority, like you just mentioned. As this has been a newer initiative, how have you seen some of those results pay off? And are you seeing positive trends there?
Absolutely. As we've talked about it, the 1 key metric -- we look at 3 key metrics for our business: patient counts, conversion and attrition. And the 1 metric that we've had the most challenge within certainly in '23, and as I said, we're improving, the new patient count. And if we look at our new patient count for the full year of 2023, we're 6% below where we were in '22. In '22 compared to '21, it was 14%. So we had an improvement from a negative 6% in '22. In the last 4 months, our new patient counts are flat. So if we look at 2023, we had 86 new patients per clinic per month compared to 91 in 2022. So we are seeing a flattening of that curve, I think we'll see that continue to improve in some of the marketing programs that our new CMO is putting in place really start taking effect.
We're also really looking more at a focus in a way we hadn't done before, not just simply at new patients, but focusing on making sure that we keep those patients with us for a longer period. Right now, the average patient that stays as a member, a little over 6 months. And so Lori is putting in new programs that will help extend that period.
And the final part of that is we're also really focused on our lapsed patients because what we know is when those patients come, they stay with us roughly with that 6 months, very often, their pain goes away, so they -- and their membership, but we can see about 25% of them will come back in the next 6 months. And so we've got programs that are being designed to really focus on that lapsed to patient to make sure that we're bringing them in sooner than they otherwise would. So I think we have some real opportunities there to develop in 2024.
Our next question comes from Jeff Van Sinderen from B. Riley.
I realize some of these questions may be a little tough due to the refranchising efforts, but all things considered, how many new licenses do you think you would sell or expect to sell this year? Maybe a targeted range there would be helpful.
Jeff, thanks for the question, and that we do not guide on franchise sales, as you know. And we talked about -- let's say, we had 55 sales for the full year '23. We know that some of the things that impacted those new sales is the economic environment, the higher interest rates, just the high employment, because there's always been kind of a relationship between unemployment and growth in franchise sales. And so there's a lot of factors there that had impacted where we were in '23 compared to '22. '22, we've sold 75 licenses. And so when we say that we're expecting there to be an impact on new license sales in '24, and we had 55 in '23, you kind of triangulate kind of where we expect that to be. And so that's kind of the way I would look at it.
That's helpful. And then sort of along the same lines of guidance. And again, I realize this is a little bit of a moving target, but based on the refranchised cadence or work that you're doing there so far at the interest levels, and I know you said it will continue into 2025, but is there a way you can help us understand. I mean, I know you gave the system-wide sales, but just -- I guess, maybe try to get to a reported sales line decline rate for FY '24, just maybe order of magnitude there. Any help you can give us there?
Yes. I mean, that's the tough part, Jeff. The GAAP revenues are going to move from being 100% recognized for a corporate location to a royalty stream as we execute the transactions. And so the depth and the breadth of that GAAP revenue decline will really be predicated on the pace and the size of some of these early transactions, which made it a really hard thing to determine from a guidance perspective for 2024. And so that's why you saw change in the guidance metrics to overall sales figures because that's where we have the predictability now. So we're not going to put out a target from a GAAP revenue basis because it's really so predicated on the timing of those transactions.
Once we finish this, I think we can get back to -- at least for us, the traditional metrics that we guide on. But it's just -- there's just too much uncertainty in terms of how this unfolds to be able to give you relevant guidance right now on EBITDA and revenue.
Understood. And then if we could shift to marketing for a minute, and I know you spoke to that. But I'm just wondering, is there any other color you can give us in terms of -- to the degree that you want to, how you're shifting the marketing? I know you mentioned maybe new channels. And just any other color you can give us there?
Sure. And I think it's really exciting to just see, of course, we have a strong CMO that's coming to place. She was the CMO of SONIC. She brings fresh eyes, she brings best programs, and quite frankly, different disciplines. So one of the first things that she's done is to go in and do an audit of all of our media buys to make sure that we're getting them the full power of them. We'll be doing some RFPs on just some of those key vendors in marketing to make sure that we're working with a partner that can most effectively support our business, that she's designed some new program phase, putting it out there, and that is where we are going to be working more with influencers. I think she's really focused on the power of our co-ops. And we have a lot of these great clusters.
And when they put their funds together that you can put an impact in that market, that, quite frankly, is uncompetable compared to anybody else, all those independents in that local market because if you have 30 or 40 units, all contributing to that local marketing spend, which you can spend that on, it's very different than if you're a sole practitioner trying to market to your clinic. So I think there's a lot of really exciting things that will be coming down the pipe and we'll get more details as we go forward.
And I also think it's just that focus on our last patients and focusing on making the patient experience better so that we can keep that patient longer could have huge implications for us. I mean, if you think about the last 7 or 8 years, we've always been so focused on new patients and really haven't spent the time we could have on that lapsed and on that -- on trying to extend the time for that patient to stay with us. So there's some real opportunities, I think, to really focus on that. Quite frankly, the improvement of the bottom line. What you should be hearing is we are highly focused on improving unit economics on that clinic level.
We know we've had some challenges with higher costs on labor over the last several years. We know we've had some issues with new patients. And so it's really incumbent upon us as a franchiser to stay laser-like focus on improving those unit economics for our franchisees, and of course, our corporate units as well.
And our next question comes from CJ Dipollino from Craig-Hallum Capital.
CJ Dipollino on for Jeremy Hamblin. I wanted to ask a quick question about sales and marketing. It looks like it was down about $1 million sequentially from Q3 to Q4. Could you give a little color on that drop and then maybe how we should think about it into the new year?
Sure. I think you'll see that normalize as we -- we tried to put it in the commentary a little bit. Through the first 3 quarters of '23, we were running a little bit hot in terms of our overall planned spend for the year in sales and marketing. So Q4, you just saw some of that normalize. As we think about our national marketing fund, the goal is to really spend that entire pool each period. And so when you've kind of accelerated some of your expenses into the earlier parts of the year, you kind of see a natural step back in Q4. So really, I think you're just seeing the timing of that play out quarter-to-quarter through 2023. So as we get back into 2024, I think you'll see that normalize again into the quarter-by-quarter cadence. Where that typically falls as Q2 and Q3 are usually a little bit heavier, Q1 and Q4 are a little bit lighter.
I think it's also important to always remember is that the bulk of the marketing that takes place in the franchise system, and certainly, in our case, is that local store marketing, which is completely off our P&L. And so yes, we have NMF that runs through the P&L, but it's really that local store marketing that each of those franchisees are spending, on average, $3,000 or more a month, is where you're seeing the real spend in our franchisees as it relates to marketing.
And then just 1 more on the P&L. Thinking about G&A moving forward, it looks like in '22, '23, it jumped up to about 69%, 70% of sales. How would you think about that moving forward in '24?
Again, I think the overall, with the refranchising strategy, we expect to see the overall G&A burden reduce considerably for the consolidated organization. Again, the timing of when we can start to reduce that G&A is really predicated on the timing of those refranchising transactions. So as we move through '24 and '25 and we begin to execute on the refranchising, all of the clinic level G&A costs will come off the books and then we'll begin to curtail the outside the 4-wall overhead as well as the corporate unallocated overhead, we expect those to reduce as we move through. And that's really the critical focus of management, understanding that for that strategy to work, we'll have to curtail the G&A expenses accordingly, and we'll stay focused on that.
And our final question today comes from Thomas McGovern from Maxim Group.
So real quick, I wanted to touch back on some of that employee retention. So based on my industry research, I've seen a lot of articles suggesting that there is going to be a fairly considerable reduction in skilled medical professionals over the coming years. So maybe if you could just go into a little bit more color on some of your plans to keep doing attractive and keep that retention rate high?
No, it's a great question. There's no question because our doctors are at the core of our business. Without doctors in chiropractic, we have no business because that's obviously the core of what we do. And that we are very much focused on working with the schools and working with associations to make them aware of The Joint, and why we are a good place for them to either become a franchisee if they have the resources or come and work for us.
If you just look at the overall market of doctors of chiropractic, there's 16 accredited schools in the United States today that graduate doctors of chiropractic. It's usually about a 3.5-year program, and those 16 schools graduate roughly between 2,400 and 2,500 doctors a year. If we come back to The Joint with our 935 clinics at the end of the year, we had a little over 3,000 doctors who are under the umbrella of The Joint, either full or part time. And so that does suggest to us. In addition to that, there's 40,000 -- or actually, there's 70,000 licensed practitioners in the United States -- in the United States today. And they have to register -- they have to license with the state if they want to practice. Not all of them are practicing. So we know there's roughly about 40,000 that are active.
And so that if you look at it from the broader scope, is that there are enough doctors to fill the growth of The Joint in the United States today, absolutely. But are there the doctors where we want them and the high-quality doctors, making sure that they stay with us, not just being recruited? So this is a hugely important effort for us, it's to maintain, to recruit and retain the best doctors in the world. But I think it's incumbent upon us to create those environments where they want to come work with us and they stay with us, as opposed to there's just theoretically not enough licensed doctors to fulfill our growth.
So last thing, you guys mentioned on the call that your portfolio mix reduced slightly, 14% of total clinics are company-owned versus 15% in 2022. You also mentioned that you expect that to -- logically, that's going to -- that's going to shift more dramatically as you guys move through this refranchising initiative. I was just wondering if you guys have maybe a targeted portfolio mix, or when the dust settles, where you guys expect the company-owned to come in as a percent of total clinics opened?
We haven't, in any way, guided on an expected percentage. But what's very clear is we've said the majority of our corporate portfolio, we expect to refranchise. And so if we ended last year with 135, I would say, by majority, we're talking about more than 51%. We don't have a final number, but it's going to be the vast majority of those corporate units will, in fact, ultimately be refranchised. So you can see that, that number is going to be pretty significantly lower than where it is today at 14%.
And ladies and gentlemen, at this time, I'd like to turn the floor back over to management for any closing remarks.
Thanks, Jamie. In February, we ran our annual Love The Joint campaign, during which our patients share their comments of The Joint on our social media. We received thousands of posts each week. So it's hard to pick the best, but I'll read a few that highlight our patient value proposition.
Casey noted, "If I missed a session, I feel terrible. My life revolves around The Joint now. It's helped me so much with my headache, I sleep better, I feel better mentally and physically. My doctor is incredibly helpful in sending me home with stretches to do and ways to treat my body better. I couldn't imagine my life without The Joint now."
Julie said, "I like that no matter where you travel, the chances are that The Joint will be there as well. Listen, I've been a member for 6 years, and I don't know how I'd manage my health wise financially without The Joint. I'm 69 years old, on a fixed budget, and being a member has totally improved my body. I'm certain, it save me money and I have the -- and I'll continue to promote The Joint. There is nothing like The Joint. Whoever thought of this and made it happen, I thank you."
And finally, Caleb reported, "The staff of my local The Joint chiropractic facility are fantastic. They've always made me feel welcome and focused on the problems that I need them to. They've been a great help in my healing journey as a disabled veteran."
Thank you, and stay well adjusted.
Ladies and gentlemen, with that, we'll be concluding today's conference call and presentation. We do thank you for joining. You may now disconnect your lines.